Vetarys

Vetarys is a veterinary biotechnology company focused on developing novel biologic therapies for companion animals. The company is advancing a pipeline targeting osteoarthritis and cancer, two of the most significant unmet needs in veterinary medicine. Its lead program, VTX-304, is a first-in-class bispecific antibody designed to simultaneously target nerve growth factor (NGF) and ADAMTS-5, providing both pain relief and cartilage protection for dogs with osteoarthritis. Vetarys is also developing VTX-301/302, a localized immunotherapy combination designed to deliver targeted cancer treatment in dogs and cats. By translating human biotechnology advances into veterinary care, Vetarys aims to meaningfully improve the quality of life and long-term outcomes for pets.